Given the observation in this study, that KIT exon 11 mutations often induce a significant response to imatinib, this highlights the importance of treating patients with unresectable or locally advanced GIST-harboring KIT exon 11 mutations with neoadjuvant imatinib. This evidence concerns the gene KIT and gastrointestinal stromal tumor.